

THE ESC TEXTBOOK OF HEART FAILURE

	Autor: Seferovic
	ISBN: 9780198891628
	Páginas: 1040
	Año: 2024
	Edición: 1
	Idioma: Ingles
	Disponible: En Stock
	Precio: 206.73 196.39
	Iva no incluido

DESCRIPTION:

The ESC Textbook of Heart Failure is the latest addition to the European Society of Cardiology (ESC) publications portfolio and is fully supported by the European Heart Failure Association.

The textbook brings together internationally renowned experts in the field of heart failure to present an up-to-date understanding of all aspects of this chronic condition that worsens with time. It is estimated that the worldwide population of patients suffering from heart failure is approximately 26 million. This clinically oriented work reflects contemporary European guidelines from the ESC and the European Heart Failure Association and summarizes the latest evidence from clinical trials.

Made up of eighteen different sections the textbook covers the epidemiology, etiology, prevention, pathophysiology, and clinical phenotypes of heart failure. The assessment and management of chronic, acute, and advance heart failure are all discussed in detail. As well as chapters dedicated to self-care and patient education, the multidisciplinary approach to heart failure management, and clinical trial design and interpretation. The future direction of the field is discussed throughout with separate chapters on digital health, big data, and telemedicine/remote monitoring in heart failure also included.

A must read for cardiovascular healthcare specialists in Europe and across the world it should also appeal to those in training, general physicians and those caring of the elderly, cardiothoracic surgeons, primary care doctors, and specialist nurses too.

CONTENTS:

Section 1: Universal definition of heart failure

1.1: Universal definition of heart failure

Section 2: Epidemiology of heart failure

2.1: Epidemiology of heart failure

Section 3: Etiology of heart failure

3.1: Coronary artery disease

3.2: Hypertension

3.3: Valvular heart disease

3.4.1: Genetic basis of cardiomyopathies

3.4.2: Dilated and hypokinetic non-dilated cardiomyopathy

3.4.3: Hypertrophic cardiomyopathy

3.4.4: Restrictive cardiomyopathy

3.4.5: Arrhythmogenic right ventricular cardiomyopathy

3.4.6: Peripartum cardiomyopathy

3.4.7: Takotsubo cardiomyopathy

3.5: Myocarditis and pericarditis

3.6: Congenital heart disease

3.7: Endocrine and metabolic disorders

3.8: Obesity

3.9: Cancer and cancer therapy

3.10: Toxins (e.g. alcohol etc.) and infections

Section 4: Prevention of heart failure

4.1: Prevention of heart failure

Section 5: Pathophysiology of heart failure

5.1: Molecular and cellular mechanisms

5.2: Alterations in myocardial metabolism

5.3: Ventricular remodelling

5.4: Neurohormonal activation

5.5: Immune-mediated mechanisms

5.6: Inflammation, oxidative stress and endothelial dysfunction

5.7: Alterations in peripheral circulation and renal function, Alterations in peripheral circulation and renal function

5.8: Systemic adaptations in metabolism and nutritive status

Section 6: Clinical phenotypes of chronic heart failure

6.1: HFrEF

6.2: HFmrEF

6.3: HFpEF

6.4: Right heart failure

Section 7: Chronic heart failure: diagnostic and prognostic assessment

7.1: Clinical assessment

7.2: Biomarkers in diagnostic and prognostic assessment

7.3: Echocardiography

7.4: Nuclear medicine

7.5: Cardiac computed tomography

7.6: Cardiac magnetic resonance

7.7: Cardiopulmonary exercise

7.8: Cardiac catheterization, invasive imaging and haemodynamic assessment

Section 8: Chronic heart failure: pharmacological management

8.1: Angiotensin converting enzyme inhibitors

8.2: Angiotensin I receptor blockers

- 8.3:ARNI
- 8.4:Beta-blockers
- 8.5:Mineralocorticoid receptor agonists
- 8.6:Ivabradine
- 8.7:Vasodilators
- 8.8:Digitalis glycosides
- 8.9:Diuretics
- 8.10:Inotropes and inodilators
- 8.11:SGLT2 inhibitors
- 8.12:Ancillary pharmacological treatment options
- 8.13:New and emerging therapies

Section 9: Chronic heart failure: non-pharmacological management

- 9.1:Implantable cardioverter defibrillator
- 9.2:Cardiac resynchronization therapy
- 9.3:Cardiac surgery
- 9.4:Valve interventions
- 9.5:Ancillary procedures
- 9.6:Cardiac rehabilitation

Section 10: Acute heart failure

- 10.1:Acute heart failure: diagnostic and prognostic assessment
- 10.2:Acute heart failure: management

Section 11: Advanced heart failure

- 11.1:Advanced heart failure: assessment
- 11.2:Advanced heart failure: management
- 11.3:Mechanical circulatory support
- 11.4:Heart transplantation
- 11.5:Palliative care and end-of-life management

Section 12: Comorbidities and clinical conditions

- 12.1:Chronic kidney disease: Clinical Aspects of Chronic Kidney Disease in Heart Failure
- 12.2:Dyskalaemia
- 12.3:Chronic lung disease
- 12.4:Ventilatory Abnormalities and Sleep Disordered Breathing
- 12.5:Pulmonary hypertension
- 12.6:Cardiac rhythm disorders
- 12.7:Management of atrial fibrillation in heart failure
- 12.8:Diabetes, metabolic syndrome and endocrine disorders
- 12.9:Systemic immune mediated diseases
- 12.10:Liver and gut dysfunction
- 12.11:Anaemia and iron deficiency
- 12.12:Depression and cognitive impairment
- 12.13:Cancer
- 12.14:Pregnancy
- 12.15:Frailty

Section 13: Self-care and patient education

- 13.1:Self-care and patient education

Section 14: Multidisciplinary approach to heart failure management

- 14.1:Multidisciplinary approach to heart failure management

Section 15: Clinical trial design and interpretation

- 15.1:Clinical trial design and interpretation

Section 16: Digital health in heart failure

- 16.1:Digital health in heart failure

Section 17: Big data in heart failure

- 17.1:Big data in heart failure

Section 18: Telemedicine and remote monitoring

- 18.1:Telemedicine and remote monitoring

LIBRERIA MEDICA BERRI 2025 ®

Dirección: Ald. Urquijo, 35 48010 Bilbao | Tlf.: 94 444 22 85 | Fax: 94 410 07 20 | libros@berri.es | www.berri.es